A Novel Self-Adjuvanting cc Particle-Based Tuberculosis Vaccine
Abstract
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, remains a major public health threat yet effective vaccines remain elusive. Mtb antigens ESAT-6 and Ag85B have shown promise as the basis of vaccines. However, developing effective immune responses to these antigens requires co-administration of immune boosters known as adjuvants, which complicates vaccine development. Another limitation of many current vaccines is the need for multiple immunizations to induce strong immunity. This proposal seeks to develop a unique Ebola virus-like particle-(eVLP)-based approach comprised of Ebola virus proteins and built in adjuvanting activity that has several advantages over existing vaccine candidates. First, introduction of the 2CARD signaling domains from the pattern recognition receptor RIG-I confers self-adjuvanting activity to the eVLPs, resulting in vigorous immune responses as compared to standard eVLPs. Second is inclusion into the platform of proven Mtb antigens that can elicit beneficial immunity. We have successfully produced highly purified eVLPs that incorporate ESAT6 and Ag85B, as well as the 2CARDdomain, in various configurations. We have previously shown that infection of cells with VLPs containing the constructs causes robust activation of innate immune responses.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2023
- Accession Number
- AD1206335
Entities
People
- Joann M. Tufariello
- Naveen Thakur
- Tshidi Tsibane
Organizations
- Georgia State University